Loading
A phase 2 trial of Belzutifan, Fulvestrant, Everolimus and Exemestane in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) is a phase 2 interventional study registered as NCT06428396 by Merck Sharp & Dohme LLC, with 120 participants enrolled, started 2024-11-27 and due to reach its primary completion in 2027-05-05. Interventions recorded: Belzutifan, Fulvestrant, Everolimus and Exemestane.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Small-molecule kinase inhibitors and the tag pipeline.
Shares Belzutifan, Merck & Co. (MSD), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.